BioAlliance Pharma: Approval of Onxeo’s admission to secondary listing and trading on NASDAQ OMX Copenhagen
July 24 2014 - 11:34AM
Business Wire
Merger exchange to take place on August 5,
2014
Regulatory News:
In continuation of their joint company announcement of July 23,
2014, BioAlliance Pharma SA (Paris:BIO) (Euronext Paris – BIO), an
innovative company specialized in the development of drugs in
orphan oncology diseases newly renamed Onxeo, and Topotarget A/S
(NASDAQ OMX Copenhagen – TOPO), today announce that NASDAQ OMX
Copenhagen has approved Onxeo’s admission to secondary trading and
official listing on NASDAQ OMX Copenhagen to be effective as of
August 1, 2014. From this date, BioAlliance Pharma as the
continuing entity after the merger will also officially operate
under the name Onxeo.
“We are very happy and proud of this final step marking the
starting point for our new identity. Onxeo’s teams are ready and
determined to unleash their synergistic potential to shape a
dynamic player in the orphan oncology market”, declares Judith
Greciet, Chief Executive Officer of Onxeo.
“With the combination of team’s expertise and a robust and
innovative pipeline, Onxeo has solid basis to successfully conduct
its mission to develop innovative drugs and provide patients with
hope and significantly improve their lives”, declares Anders
Vadsholt, Chief Executive Officer of Topotarget.
For more information on Onxeo reference is made to the admission
prospectus of May 26, 2014 prepared by Onxeo and the company
announcements issued by Onxeo, which are available on Onxeo’s
website (www.bioalliancepharma.com). There has been no adverse
material change in Onxeo compared with the information provided in
the admission prospectus dated May 26, 2014.
BioAlliance Pharma’s shares (including the newly issued shares)
will remain admitted to trading on Euronext Paris under the name
Onxeo (ticker: ONXEO).
The exchange of the Topotarget A/S shares against Onxeo's new
ordinary shares in accordance with the merger plan is expected to
occur on August 5, 2014.
Timetable:
Event Expected Date Issuance of legality
certificate by French authority July 22, 2014 Registration
by the Danish Business Authority of completion of the merger and
deregistration of Topotarget A/S July 28, 2014 Last day of
trading of Topotarget A/S on NASDAQ OMX Copenhagen July 31,
2014 Admission to trading of Onxeo's new ordinary shares on
Euronext Paris August 1, 2014 Name change to Onxeo effective
on Euronext Paris August 1, 2014 First day of trading of
Onxeo SA on NASDAQ OMX Copenhagen in ISIN FR0010095596 (ticker:
ONXEO) August 1, 2014
Exchange of Topotarget shares with new
ordinary shares in Onxeo SA through VP Securities (end of day) in
accordance with the exchange ratio definedin the merger plan (2
Onxeo shares for each set of 27 Topotarget shares)
August 5, 2014 Settlement of payment for fractional
entitlements August 6, 2014
About BioAlliance PharmaDedicated to cancer treatments
with a focus on resistance targeting and orphan products,
BioAlliance Pharma conceives and develops innovative products for
orphan or rare diseases.Created in 1997 and introduced to the
Euronext Paris market in 2005, BioAlliance Pharma’s ambition is to
become a leading player in these fields by coupling innovation to
patient needs. The company’s teams have the key competencies
required to identify, develop and register drugs in Europe and the
USA.For more information, visit the BioAlliance Pharma web site at
www.bioalliancepharma.com
About TopotargetTopotarget (NASDAQ OMX: TOPO) is a
Danish-based biopharmaceutical company headquartered in Copenhagen,
Denmark, dedicated to clinical development and registration of
oncology products. In collaboration with Spectrum Pharmaceuticals,
Inc., Topotarget focuses on the development of its lead drug
candidate, belinostat, which has shown positive results in the
treatment of hematological malignancies and solid tumors, obtained
by both mono- and combination therapy.For more information, please
refer to www.topotarget.com.
About OnxeoOnxeo will aim at becoming a global leader on
the fast-growing market of orphan oncology drugs. It will hold a
complementary portfolio of advanced programs targeting severe
pathologies for which there is an unmet medical need. Onxeo will
offer reinforced market attractiveness, notably towards specialized
international investors, through a more important critical mass, a
European scale, and a portfolio of high value-added products.
Disclaimer
This communication expressly or implicitly contains certain
forward-looking statements concerning BioAlliance Pharma SA and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors, which could cause the actual
results, financial condition, performance or achievements of
BioAlliance Pharma SA to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. BioAlliance Pharma SA is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.
For a discussion of risks and uncertainties which could cause
actual results, financial condition, performance or achievements of
BioAlliance Pharma SA to differ from those contained in the
forward-looking statements, please refer to the Risk Factors
("Facteurs de Risque") section of the 2013 Reference Document filed
with the AMF on April 7, 2014, which is available on the AMF
website (http://www.amf-france.org) or on BioAlliance Pharma SA's
website (www.bioalliancepharma.com).
BioAlliance Pharma:Judith Greciet, +33 1 45 58 76 00Chief
Executive OfficerNicolas Fellmann, +33 1 45 58 76 00Chief Financial
OfficerorAlizéeRP:Caroline Carmagnol, +33 6 64 18 99
59orTopotarget:Bo Jesper Hansen, +45 26 12 83 84Executive
Chairman of the BoardAnders Vadsholt, +45 28 98 90 55Chief
Executive OfficerorImpact Communications:Michael
Steen-Knudsen, +45 25 17 18 15
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Apr 2023 to Apr 2024